Tag Archive for: abiraterone acetate
AMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: Darolutamide Triplet Therapy Outperforms Alternatives in Advanced Prostate Cancer
/in Retrospective studies/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/in Observational, Retrospective studies/by MaxPhase 1 Clinical Trial: The PHAROS Trial Investigates Novel ACK1 Inhibitor
/in Clinical Trial, Metastatic, Phase 1/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026